FcεRI cross-linking did not trigger degranulation 5 . The authors noted that the phospholipase-Cγ signaling pathway was activated as expected, prompting them to examine a secondary calcium release pathway that is phospholipase-Cγ independent.
This second pathway, which involves phospholipase D and sphingosine kinase, induces a transient early calcium flux after FcεRI ligation. Melendez et al. 5 found that neither of these enzymes were activated after FcεRI cross-linking in the presence of ES-62. In monocytes, PKC-α couples phospholipase D to FcR signaling 9 . By using antisense RNA to lower the expression of PKC-α in mast cells, the authors showed that the sphingosine kinase pathway has a crucial role in FcεRI-triggered activation 5 . The authors found that PKC-α regulates the release of the pre-formed mediators such as histamine, and also the production of lateresponse components such as leukotrienes, prostaglandins and several proinflammatory cytokines 5 . These findings emphasize a previously underappreciated role for PKC-α in mast cell activation. Melendez et al. 5 then looked into how ES-62 represses this alternative calcium release cascade and, consequently, inflammation. Previous experiments from the Harnetts' laboratories showed that the receptor for ES-62 is TLR4, the innate receptor for the bacterial cell-wall component lipopolysaccharide. In this new study, the authors show that ES-62 signals through TLR4 to prevent FcεRI-initiated mast cell signaling. Melendez et al. 5 observed internalized ES-62-TLR4 complexes that recruit large amounts of PKC-α, thereby reducing the availability of this enzyme for FcεRI signaling 5 . Importantly, the interaction between lipopolysaccharide and TLR4 did not recruit PKC-α and did not inhibit FcεRI-triggered signaling.
Thus, ES-62 manipulates TLR4 to sequester a key signaling intermediate, PKC-α, away from the FcεRI pathway, preventing degranulation (Fig. 1) . PKC-α activity is further repressed because the interaction with the ES-62-bound TLR4 marks PKC-α for degradation in a little-studied perinuclear degradation site 10 . It remains unclear whether ES-62's modulatory roles in other immune cells involve processes fundamentally similar to those at work in mast cells.
Melendez et al. 5 concluded their study with a hint that this helminth-derived protein might lead to the development of realworld therapeutics for allergies and asthma. They showed that ES-62 can prevent mast cell-dependent cutaneous and pulmonary allergic reactions in vivo. As the authors point out, with regard to its potential as a candidate for a drug base, ES-62 has in its favor the fact that the millions of people who are infected with filarial worms tolerate them for years on end-which is exactly what is needed in a drug intended for the ongoing treatment of a chronic condition such as asthma. From previous work, it appears that many of ES-62's immunomodulatory properties are dependent on phosphorylcholine 1 . New therapeutics may be derived from this small compound, which already forms a base for several medically relevant products, from contact lens solutions to the new antileishmanial drug miltefosine.
In contrast to what we now know about the effects of ES-62 on mast cells, we know little about what ES-62 does for the parasites that make it. That its sole role is to allow the parasite to regulate host immunity is an assumption. The implication would be that filarial worms unable to produce ES-62-like molecules would induce unusually serious inflammation, perhaps resulting in either eradication of the infection or acutely lethal disease. Either of these situations would be less than optimal for the parasite, and both such outcomes have been observed in other types of helminth infections in which host, rather than parasite, immunoregulatory mechanisms are compromised 11, 12 . Recent developments in the application of RNAi in filarial nematodes 13 indicate that these exciting issues may soon be investigated in vivo.
Metastases are derived from distinct subpopulations of cells that exist within a tumor. In a classic example, the melanoma cell subtype B16 can be selected from a primary tumor and enriched for an increased tendency to colonize lung 1 . Tumor cell behavior, however, is often remarkably plastic. The cells have some properties reminiscent of those of cells undergoing epithelialmesenchymal transition (EMT), a normal developmental process in which embryonic cells temporarily disrupt tissue architecture by disassembling junctional structures, and then expressing mesenchymal proteins and migrating 2 . It has been hypothesized that in cancers, EMT confers motility by changing cell-cell interactions and adhesive characteristics.
Some researchers have put forward the idea that the EMT pathway is usurped by tumor cell populations so that they become transiently metastatic 3 . A recent study in Nature by Weinberg and colleagues supports another possible mechanism: mesenchymal stem cells within a primary tumor might elicit a transient enhancement of metastasis 4 .
Metastases develop as the culmination of the so-called 'metastatic cascade', a multistep sequential process in which tumor cells depart the primary tumor, enter the lymphatic system, blood system or body cavity, arrest at nearby or distant sites, and again proliferate to colonize ectopic tissues.
There is a long history of clinical and experimental observations showing that metastases frequently occur at sites of injury. Because stem cells preferentially migrate to tumors and sites of tissue injury 5 , they may prepare the site(s) for subsequent colonization. Once there, hematopoietic stem cells are recruited to a so-called 'premetastatic niche', where they reorganize the matrix and establish sites at which tumor cells proliferate more frequently than at other locales to develop bona fide metastases 6 . Karnoub et al. 4 embarked upon their study to determine whether infiltrating mesenchymal stem cells (MSCs) could alter tumor cell behavior.
The authors showed that weakly metastatic human breast cancer cells acquired an increased ability to disseminate to the lungs when they were mixed with MSCs before being subcutaneously injected 4 . Primary tumor growth was unaffected by the presence of MSCs. Because carcinoma cells isolated from secondary tumors in the lungs were no more metastatic than the parental cells, the authors concluded that the enhancement of 'metastasis' was transitory. However, markers of EMT were not upregulated in the tumor cells, suggesting that other mechanisms for inducing metastasis are operating in this system.
The authors found that tumor cells instead induced expression of the chemokine CCL5 in the MSCs, suggesting that CCL5 may increase the motility of the tumor cells or contribute to feedback signals sent to the tumor cells via a paracrine or juxtracrine loop 4 . Still, exactly how CCL5 regulates metastasis is uncertain.
The Karnoub et al. 4 study adds to the growing body of evidence that tumor-stromal cross-talk 7 and genetic background are essential to the behavior of a tumor. But this study is not the first to show that various stem cells and their progeny contribute to invasive and metastatic behavior. Taketo and colleagues recently showed that myeloid stem cells that were recruited to primary colon tumors enhanced the tumors' invasiveness 8 . Others have shown that tumor-elicited macrophages and neutrophils increase metastatic efficiency by enhancing invasion through basement membranes 9, 10 . Additionally, tumor angiogenesis builds or recruits new capillaries through the mobilization of angio- blasts, among other processes 11 . Together, these data highlight how metastatic cells can co-opt other cells to assist them.
Importantly, metastasis is not simply the movement of cells around the body. Clinically relevant secondary tumors must grow to a size that impairs local physiology. In short, to become a bona fide metastasis, disseminated cells must colonize ectopic tissues 12 . Karnoub et al. 4 used GFP-expressing tumor cells to visualize single cells within tissues. They found that there were more small green foci in the lungs when MSCs were mixed with the cancer cells before injection 4 as compared to the amount seen in tumor cells alone. It does not appear, however, that there were substantially more macroscopic tumors (that is, metastases) under these conditions, suggesting that there was increased dissemination of cancer cells, but not necessarily increased metastasis. Notwithstanding this crucial nuance, the data are potentially noteworthy because more disseminated cells should, in theory, translate into increased metastasis. Unfortunately, the measurement of an increased amount of circulating cancer cells has not always correlated with the development of metastasis 13 .
Another minor experimental caveat to the Karnoub et al. 4 study is that they did not test whether the observed high rate of dissemination would occur if the tumor cell injections were done at an orthotopic site (such as a mammary fat pad), where the extracellular milieu is unique and tissue architecture may affect the behavior of the injected cells 14 .
Unlike the MSCs in the Karnoub et al. 4 study, stem cells are not always protumorigenic and prometastatic. Khakoo and colleagues showed that MSCs have antitumor effects against Kaposi's sarcoma 15 . The knowledge that MSCs localize to sites of tissue injury (as would occur when tumor cells remodel the extracellular matrix) and may have antitumor effects has led many groups to try using MSCs as an anticancer therapy. Whether MSC therapy would apply to all tumor types is unknown. But the data from Karnoub et al. 4 suggest that care should be taken to watch for additional metastases if MSC numbers in the primary tumors are increased.
Ultimately, Karnoub et al. 4 have resurrected the idea of a transiently metastatic cell state and have proposed a potential molecular mechanism. At first glance, the existence of temporarily metastatic cells would seem to undermine the overwhelming body of data supporting a genetically stable metastatic phenotype 1 . That conclusion, however, would be overstated. Some tumor cells may be more effective at manipulating host cells to do their 1 2 9 0 VOLUME 13 | NUMBER 11 | NOVEMBER 2007 NATURE MEDICINE bidding at various steps of the metastatic cascade, including the colonization of ectopic tissues. The Karnoub et al. 4 report contributes to the many studies that show how metastatic cells compensate for intrinsic defects or supplement essential pathways by taking advantage of stem cells to assist them in various steps of the metastatic cascade (Fig. 1) . The 'take-home' message from all of these studies is that the most lethal attributes of tumor cells are not going to be neutralized if the research community blindly looks only at the tumor cell or only at the stroma-the interactions between the two are crucial. Although the complexity of these interactions is daunting, the silver lining is that stem cells may provide researchers with new targets to focus future therapies on. Just as importantly, some of the dusty hypotheses related to mechanisms of metastasis should be revisited because of this new understanding of cellular interactions. As neoplastic cells evolve toward aggressive metastatic behavior, a missing link may now be found in the recruited cell populations.
